Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced the execution of a royalty acquisition agreement ("Agreement") with HealthCare Royalty Partners ("HC Royalty"). Per the Agreement, HC Royalty will make a $30 million cash payment to Supernus in consideration for acquiring from Supernus certain royalty and milestone rights related to the commercialization of Orenitram(TM) (treprostinil) Extended-Release Tablets by Supernus' partner United Therapeutics Corporation. Supernus will retain full ownership of the Royalty Rights after a certain threshold has been reached per the terms of the Agreement.
"We are pleased to have completed this royalty transaction, which strengthens our balance sheet and enhances our financial flexibility," said Jack Khattar, President and Chief Executive Officer of Supernus. "The transaction allows us to partially monetize our royalty stream from Orenitram(TM) for a significant cash consideration while positioning Supernus to further benefit from the future upside potential of the product."